Previous close | 31.83 |
Open | 31.34 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 31.34 - 31.50 |
52-week range | 19.76 - 34.39 |
Volume | |
Avg. volume | 2,301 |
Market cap | 60.072B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 130.58 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.24 (0.74%) |
Ex-dividend date | 30 Mar 2023 |
1y target est | N/A |
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.
Shares in the Anglo-Swedish drugs giant fell 0.4% in afternoon trade in London.